Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in manufacturing and trading medicines, including generic drugs.[1]
- Market Cap ₹ 163 Cr.
- Current Price ₹ 95.3
- High / Low ₹ 154 / 52.8
- Stock P/E 17.1
- Book Value ₹ 39.6
- Dividend Yield 0.52 %
- ROCE 27.4 %
- ROE 26.4 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.1%
Cons
- Company has high debtors of 187 days.
- Working capital days have increased from 103 days to 155 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|
| 78 | 72 | 92 | 115 | 132 | 130 | |
| 71 | 64 | 85 | 105 | 115 | 117 | |
| Operating Profit | 7 | 7 | 7 | 9 | 17 | 13 |
| OPM % | 9% | 10% | 8% | 8% | 13% | 10% |
| 0 | 0 | 1 | 1 | 1 | 3 | |
| Interest | 1 | 1 | 2 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 5 | 4 | 7 | 13 | 11 |
| Tax % | 30% | 33% | 27% | 27% | 28% | |
| 3 | 3 | 3 | 5 | 10 | 10 | |
| EPS in Rs | 5.56 | 5.58 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 51% |
| TTM: | 117% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 28% |
| Last Year: | 26% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 | 0.40 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 51 |
| 12 | 15 | 17 | 25 | 24 | 40 | |
| 25 | 21 | 37 | 54 | 48 | 36 | |
| Total Liabilities | 44 | 47 | 66 | 97 | 134 | 144 |
| 6 | 9 | 10 | 11 | 11 | 11 | |
| CWIP | 3 | 0 | 0 | 0 | 4 | 21 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 35 | 37 | 56 | 86 | 119 | 112 | |
| Total Assets | 44 | 47 | 66 | 97 | 134 | 144 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 3 | -1 | 5 | -4 | -12 | |
| -5 | -2 | -3 | -2 | 26 | |
| 1 | 3 | -1 | 6 | -4 | |
| Net Cash Flow | -0 | -0 | 1 | -0 | 9 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | 157 | 187 |
| Inventory Days | 29 | 52 | 67 | ||
| Days Payable | 155 | 155 | 190 | ||
| Cash Conversion Cycle | -7 | 17 | 5 | 157 | 187 |
| Working Capital Days | 26 | 66 | 58 | 96 | 155 |
| ROCE % | 28% | 24% | 25% | 27% |
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
14 November 2024 - Zenith Drugs Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
-
Statement of deviation(s) or variation(s) under Reg. 32
14 November 2024 - Zenith Drugs Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
-
Financial Result Updates
14 November 2024 - Zenith Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
-
Outcome of Board Meeting
14 November 2024 - Zenith Drugs Limited has informed regarding Board meeting held on November 14, 2024.
-
Board Meeting Intimation
9 November 2024 - ZENITH DRUGS LIMITED has informed about Board Meeting to be held on 14-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company …
Product Portfolio[1]
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals;
Capsules